|Cat. No. HS-398 108||100 µl purified recombinant IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O. Then aliquot and store at -20°C to -80°C until use.|
ICC: 1 : 500 gallery
IHC: 1 : 500 (see remarks) gallery
IHC-P/FFPE: 1 : 500 gallery
|Subtype||IgG1 (κ light chain)|
|Immunogen||Synthetic peptide corresponding to AA 1234 to 1252 from mouse Ki67 (UniProt Id: E9PVX6)|
Epitop: AA 1234 to 1252 from mouse Ki67 (UniProt Id: E9PVX6)
Reacts with: mouse (E9PVX6).
No signal: human (P46013), rat (D4A0Y6).
Other species not tested yet.
|Specificity||Specific for Ki 67|
This antibody is a chimeric antibody based on the monoclonal rat antibody clone 311H2. The constant regions of the heavy and light chains have been replaced by rabbit specific sequences. Therefore, the antibody can be used with standard anti-rabbit secondary reagents. The antibody has been expressed in mammalian cells.
Indirect immunostaining of a formalin fixed paraffin embedded wild-type mouse spleen section (left) and identical treated section of a mouse spleen engrafted with human CD34+-cells (right; kindly provided by Charles River Discovery Research Services Germany GmbH, Freiburg, Germany) unsing rabbit anti-mouse Ki67 (cat. no. HS-398 108, dilution 1:500; green) and rat anti-human Lamin B1 (cat. no. HS-404 017, dilution 1:100; red). Nuclei have been visualized by DAPI stainin (blue).
Expression of the nuclear protein Ki 67 is strictly associated with cell proliferation and preferentially expressed during the late G1, S, G2 and M phases of the cell cycle. Resting cells (G0 phase) lack Ki 67 expression .
Immunohistochemical detection of Ki 67 is a simple and reproducible method to determine the tumour proliferative index and is a predictive and prognostic biomarker in certain types of human cancer, such as breast cancer, gastric cancer or prostate cancer. Moreover, higher Ki 67 scores may be associated with increased tumor sensitivity to radiation therapy and chemotherapy.
In preclinical and clinical studies Ki 67 expression is used as a pharmacodynamic biomarker. Absence of a decrease in Ki 67 early in treatment might be predictive of therapeutic failure.